<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668146</url>
  </required_header>
  <id_info>
    <org_study_id>0042</org_study_id>
    <nct_id>NCT02668146</nct_id>
  </id_info>
  <brief_title>An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor</brief_title>
  <official_title>A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Greater Los Angeles Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Greater Los Angeles Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obtain information on whether the medication Perampanel reduces tremor in people with
      essential tremor and is well-tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see descriptions in &quot;Primary and Secondary Outcomes&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tremor reduction. TETRAS scale, performance sub scale.</measure>
    <time_frame>40 weeks</time_frame>
    <description>This scale evaluates tremor of various body parts during postures, movement and tasks. Items are scored from 0 to 4, with 4 representing highest severity. Maximum score is 64.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tremor reduction. TETRAS scale. Activity of Daily Living subscale.</measure>
    <time_frame>40 weeks</time_frame>
    <description>The subject rates to what extent tremor affects activities in a 12-item, 0-to-4 scale. Maximum score is 48.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tremor reduction. TETRAS scale. Subject Global Impression of Change.</measure>
    <time_frame>40 weeks</time_frame>
    <description>Subjects rate the degree of change from minus 3 to plus 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tremor reduction. TETRAS scale. QUEST subscale (QUality of life in Essential Tremor).</measure>
    <time_frame>40 weeks</time_frame>
    <description>30-item questionnaire in which the subject rates on a 0 to 4 scale how much tremor affects aspects of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety. vitals;</measure>
    <time_frame>40 weeks</time_frame>
    <description>Weight (lbs), respiration rate (rps), heart rate (bps) and blood pressure (mmhg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability. Adverse Events.</measure>
    <time_frame>40 weeks</time_frame>
    <description>At each clinic and phone visit, the PI and coordinator will collect information on any adverse events. An Adverse Event will be defined as any clinically undesirable event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety; laboratory testing</measure>
    <time_frame>40 weeks</time_frame>
    <description>At each clinic visit. Laboratory testing will be done. This will include metabolic panel (serum electrolytes, glucose (mg/dl) , creatinine (mg/dl) , calcium (mg/dl), magnesium (mg/dl), Complete Blood Count(CBC) (mg/dl), White Blood Count (WBC) (k/ul), platelets (k/ul), hepatic panel (total BILIRUBIN, Total PROTEIN, ALKALINE PHOSPHATASE, ALANINE AMINOTRANSFERASE, ASPARTATE AMINOTRANSFERASE, ALBUMIN GLUTAMYL TRANSFERASE LDH), and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety. Laboratory testing; screen visit testing</measure>
    <time_frame>screen visit</time_frame>
    <description>Screen Visit testing will include hemoglobin A1c (%), free thyroxin (ng/dl), and Thyroid Stimulating Hormone (TSH) (uIU/mL) . An EKG will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment effects on Daily Living (The QUEST scale to assess quality of life)</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assess the effect of treatment on tremor-affected activities of daily living. The QUEST scale to assess quality of life in essential tremor. It is a 30-item questionnaire in which the subject rates on a 0 to 4 scale how much tremor affects aspects of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIE changes</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assess changes in Quality Of Life (QOLIE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of global life changes</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assess subject global impression of change as a result of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>perampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perampanel administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered to subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Study drug will be administered to study subjects</description>
    <arm_group_label>perampanel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered to study subjects</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has reviewed, signed and dated a written informed consent form and use of
             protected health information [Health Insurance Portability and Accountability Act
             (HIPAA) Authorization], including videotaping consent.

          2. Subject is 18 or older.

          3. Subject has a diagnosis of definite or probable essential tremor (ET) as defined by
             the Tremor Investigational Group, with involvement of the hands and arms of at least 2
             years duration, without present causes of enhanced physiologic tremor, no recent
             exposure to tremorogenic drugs or drug withdrawal states, no direct or indirect trauma
             to the nervous system within 3 months preceding the onset of tremor, and no historic
             or clinical evidence of psychogenic tremor origin.

          4. Tremor severity score of at least 2 in at least one upper extremity on the
             Fahn-Tolosa-Marin Tremor Rating Scale, or at least 1.5 on the TETRAS scale.

          5. Subject is taking the same dose of one to three anti-tremor medications for at least 4
             weeks prior to screening, has an inadequate response to that/those medication(s), and,
             barring any unforeseen circumstances, will continue for the duration of the study on
             the same dose(s) of anti-tremor medication(s), OR Has failed at least one course of an
             anti-tremor medication and cannot tolerate available anti-tremor medication(s), OR Is
             naive to anti-tremor treatment and refuses to take available anti-tremor medications.

          6. If a woman of childbearing potential:

             A. Must be unable to become pregnant or use adequate birth control; B. Must be defined
             as status post hysterectomy or tubal ligation, or 2 years post-menopausal, OR C.
             Otherwise documented to be incapable of pregnancy, or have practiced one of the
             following methods of contraception for at least two months prior to screening: 1)
             hormonal contraceptives, 2) spermicide and barrier method, 3) intrauterine device, 4)
             partner sterility, 5) abstinence, and have a negative pregnancy test during screening.

          7. Subject is accessible by telephone.

          8. Subject can comply with study visits, study drug compliance, and study procedures.

          9. Subject is on stable doses of all other medications for at least 4 weeks prior to the
             first baseline visit, and, barring any unforeseen circumstances, for the duration of
             the study

        Exclusion Criteria:

          1. Subject's tremor is adequately controlled on a current treatment.

          2. Subject is pregnant, plans to become pregnant during the study or within 2 months of
             completing the study or who is presently lactating or breast-feeding.

          3. Subject has other medical conditions that may cause or explain subject's tremor, such
             as but not limited to, Parkinson's disease, hyperthyroidism, pheochromocytoma, head
             trauma or cerebrovascular disease within 3 months prior to the onset of essential
             tremor; multiple sclerosis, polyneuropathy or family history of Fragile X syndrome.

          4. Subject taking medication(s) that might produce tremor or interfere with the
             evaluation of tremor, such as but not limited to: CNS-stimulants, stimulant
             decongestants, beta-agonist bronchodilators, lithium, amiodarone, metoclopramide,
             theophylline, valproate, Irregular use (&quot;as needed&quot; or &quot;prn&quot;) of benzodiazepines,
             sleep medications or anxiolytics; (However, regular use of a benzodiazepine, sleep
             medication or anxiolytic to improve sleep or performance is allowed as long as tremor
             persists against the background of regular medication use)

          5. Subject has had surgical intervention for their tremor in the past (e.g., ablative
             thalamotomy or gamma knife thalamotomy), or has had a botulinum toxin injection in the
             6 months prior to screening

          6. Subject has used an experimental drug within the 4 weeks prior to screening (or within
             5 half-lives, whichever is longer) for any reason, OR has used a device for the
             treatment of essential tremor in the 4 weeks prior to screening, OR has ever used deep
             brain stimulation for any reason

          7. Subject cannot abstain from the use of the following drugs for the stated period of
             time prior to a clinic visit: caffeine (8 hours) and alcohol (12 hours).

          8. Subject cannot abstain from use of alcohol prior to driving vehicle or operating heavy
             machinery.

          9. Subject with a history in the last 2 years of alcohol or substance abuse (DSM 305); or
             history of consuming more than 2 glasses of wine (or equivalent) per day in the last
             28 days prior to screening.

         10. Subject with a history of significant psychiatric disorder (e.g., mania, bipolar
             depressive disorder, schizophrenia, schizoaffective disorder, or other major
             psychiatric disorder), significant coagulation, immunologic, gastrointestinal,
             respiratory, cardiovascular (e.g., uncontrolled hypertension, myocardial infarction in
             the last 18 months, significant bundle branch block, congestive heart disease),
             endocrine (e.g., uncontrolled diabetes, hyperthyroidism) disorder, or current or
             chronic infection, significant Screening laboratory or ECG abnormalities, or any acute
             or chronic illness or abnormality which in the opinion of the Investigator precludes
             study participation. Subject with Right Bundle Branch Block, pacemakers, controlled
             asthma or controlled hypertension and/or controlled diabetes (hemoglobin A1c &lt; 8%) are
             acceptable, as are subjects with thyroid disease, provided they are euthyroid on
             treatment. Subject with single or recurrent episodes of major depressive disorder (DSM
             IV 296.20 -.25 or 296.30-.35) that have been successfully managed with a stable dose
             (over 60 days) of an antidepressant may be considered for entry.

         11. Subject with liver disease that is more than mild. This is defined as transaminase
             levels AST and ALT greater than 50% above normal.

         12. Subject with severe renal disease, defined as having creatinine clearance less than 39
             ml/min.

         13. Subject has had a suicide attempt, suicidal ideation with intent, or history of
             aggression, including but not restricted to violence or threat of violence, within the
             past 2 years.

         14. Subject with a recent history of hematologic/oncologic disorders (within 2 years),
             other than successfully resolved cutaneous basal cell or squamous cell carcinomas.
             Stability after treatment for prostate cancer is also acceptable.

         15. Subject with clinically significant impaired balance or considered at increased risk
             for falls.

         16. Subject is taking phenytoin, carbamazepine, oxycarbazine, rifampin, St John's wart,
             ketonazole or consuming grapefruit juice.

         17. Subject with history of taking perampanel in the past. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles A Handforth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VHAGLAHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Greater Los Angeles Healthcare System</investigator_affiliation>
    <investigator_full_name>Adrian Handforth, MD</investigator_full_name>
    <investigator_title>Assistant Chief of Staff, Neurology VAGLAHS</investigator_title>
  </responsible_party>
  <keyword>essential tremor</keyword>
  <keyword>Perampanel</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

